Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced that Chief Executive Officer Marc Viscogliosi will present a corporate overview and update at Biotech Showcase 2025, taking place in San Francisco January 13-15.
Biotech Showcase 2025 Presentation Details
Date: Tuesday, January 14, 2025
Time: 3:00 PM PT
Venue: Hilton San Francisco Union Square Hotel, San Francisco, CA (United States)
Room: Franciscan-B
About SB-01 For Injection
SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by almost every tissue and cell type, is stored in abundance in the extracellular matrix, and possesses suppressive and stimulatory signaling pathways. In many diseases, there are high concentrations of TGF-Beta that result in a spectrum of negative downstream effects including inflammation, fibrosis, neoinnervation, hyperexcitability of nerves and cell proliferation. SB-01 modulates TGF-Beta concentration, without eliminating it, mitigating the negative downstream effects.
About Spine BioPharma
Spine BioPharma is committed to developing non-opiate, non-surgical treatments that will reduce pain, restore function, and slow or stop pathological disease progression. Spine BioPharma’s lead candidate, SB-01 For Injection, is a first-in-class treatment of DDD, offering potential clinical benefits of pain relief, restoration of function, and prevention of disease progression. To learn more about Spine BioPharma, visit www.spinebiopharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107142335/en/
Contacts
Corporate Inquiries:
Jason Gallagher
Chief Commercial Officer & Chief Operating Officer
Spine Biopharma, Inc.
212-583-9700
jgallagher@spinebiopharma.com
Media Inquiries:
Sasha Damouni Ellis
Damouni Group LLC
sasha@damounigroup.com
